Last reviewed · How we verify
Mycophenolic acid dose reduction
Mycophenolic acid dose reduction involves lowering the administered dose of mycophenolic acid, an immunosuppressant that inhibits inosine monophosphate dehydrogenase (IMPDH) to reduce T and B lymphocyte proliferation.
Mycophenolic acid dose reduction involves lowering the administered dose of mycophenolic acid, an immunosuppressant that inhibits inosine monophosphate dehydrogenase (IMPDH) to reduce T and B lymphocyte proliferation. Used for Prevention of organ rejection in transplant recipients (kidney, heart, liver), Autoimmune diseases requiring immunosuppression.
At a glance
| Generic name | Mycophenolic acid dose reduction |
|---|---|
| Also known as | CellCept, Myfortic |
| Sponsor | University of California, San Francisco |
| Drug class | Immunosuppressant |
| Target | Inosine monophosphate dehydrogenase (IMPDH) type II |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Mycophenolic acid is a selective inhibitor of IMPDH type II, an enzyme critical for guanosine nucleotide synthesis in lymphocytes. By reducing the dose, this approach aims to maintain immunosuppressive efficacy while decreasing exposure-related adverse effects. Dose reduction strategies are typically employed in transplant recipients to optimize the balance between rejection prevention and tolerability.
Approved indications
- Prevention of organ rejection in transplant recipients (kidney, heart, liver)
- Autoimmune diseases requiring immunosuppression
Common side effects
- Gastrointestinal disturbances (diarrhea, nausea, vomiting)
- Leukopenia
- Infection
- Anemia
Key clinical trials
- Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies (PHASE2)
- Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita (PHASE2)
- MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases (PHASE2)
- Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients (PHASE2)
- The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation (PHASE1, PHASE2)
- Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation (PHASE2)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- Reduced Intensity Haploidentical BMT for High Risk Solid Tumors (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: